{"type":"trials","record":{"id":87186,"source_id":"isrctn","external_id":"ISRCTN34221234","title":"Greater Manchester Avastin® for choroidal Neovascularisation trial","brief_summary":"The aim of the study is to demonstrate that a treatment regime over 12 and 24 months where intravitreal bevacizumab for treatment of neovascular age-related macular degeneration is given monthly for three months and then on a prn ('when necessary') basis at three monthly intervals, the 'PRN' treatment arm, is not inferior to a regime where bevacizumab is given monthly for three months and then every three months irrespective of clinical symptoms and signs, the 'Routine' treatment arm, with respect to best-corrected visual acuity (BCVA).","overall_status":"Completed","phases":["Not Applicable"],"study_type":"Interventional","sponsor":"Central Manchester & Manchester Children's Hospital NHS Trust (UK)","enrollment":330,"countries":["United Kingdom","England"],"start_date":"2008-02-03","completion_date":"2011-04-30","last_update_date":"2017-04-12","source_url":"https://www.isrctn.com/ISRCTN34221234","editorial_summary":"A registered Not Applicable study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Senior","comparator":null,"attribution":"Source: ISRCTN ISRCTN34221234; retrieved 2026-09-25","interventions":["Bevacizumab (Avastin®)","Drug"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["1. Visual acuity outcomes. Duration of follow-up: 24 months 2. Safety: adverse event reports and vital signs. Duration…","1. Investigation of equivalence between two arms using additional measures of visual function including contrast sensit…"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Age-related macular degeneration","Initially, all participants will be treated with 1.25 mg intravitreal bevacizumab (Avastin®) on Day 1 and 1 and 2 month…","Bevacizumab (Avastin®)","Drug"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":50,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn34221234","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2008-02-03 to 2011-04-30","comparator":null,"confidence":"structured-source","population":"All · Senior","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.596Z","intervention":["Bevacizumab (Avastin®)","Drug"],"participants":330,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Not Applicable","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["1. Visual acuity outcomes. Duration of follow-up: 24 months 2. Safety: adverse event reports and vital signs. Duration…","1. Investigation of equivalence between two arms using additional measures of visual function including contrast sensit…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87186","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}